Pancreatic cancer drug fast-tracked by EU regulator
The European Medicines Agency (EMA) has begun an accelerated assessment of a potential new treatment for metastatic pancreatic cancer. Noting that pancreatic cancer is an area of high… read more.
The European Medicines Agency (EMA) has begun an accelerated assessment of a potential new treatment for metastatic pancreatic cancer. Noting that pancreatic cancer is an area of high… read more.
AstraZeneca’s Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been approved in the European Union for the treatment of adult… read more.
NICE (UK): Cemiplimab can be used as an option to treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy in adults if: i)… read more.
AstraZeneca withdrew its application for the use of Imfinzi (durvalumab) in combination with BCG in the treatment of high-risk non-muscle invasive bladder cancer (NMIBC), a type of cancer… read more.
Gilead Sciences announced that the CHMP of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy (sacituzumab govitecan-hziy) in combination with… read more.
Pfizer announced that the FDA accepted for Priority Review a supplemental New Drug Application (sNDA) for Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with… read more.
Celcuity Inc. announced that the FDA approved Revtorpyk (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally… read more.
GSK plc announced the FDA has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung… read more.
NICE(UK): Pembrolizumab with chemoradiotherapy (external beam radiation therapy followed by brachytherapy) can be used, within its marketing authorisation, as an option for untreated International Federation of Gynecology and… read more.
According to the MHRA website, the MHRA approved Retifanlimab (Zynyz) as the first treatment given to adults with advanced Merkel cell skin cancer that has spread or returned… read more.
More than 50 million Americans live in counties without a radiation oncology practice site and millions more are at risk, according to a new study published today in the International Journal… read more.
Pfizer Inc. announced the FDA approved Ibrance (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.